Trial · NCT07602062
Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis
NCT07602062, Not applicable, Not yet recruiting, Shanghai Zhongshan Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis. Trials, record NCT07602062. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07602062
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis
- NCT number
- NCT07602062
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 175 participants, estimated
- Lead sponsor
- Shanghai Zhongshan Hospital
- Conditions
- Portal Vein Thrombosis, Anticoagulant Therapy, Variceal Bleeding
- Interventions
- Rivaroxaban
- First posted
- 2026-05-22
- Last updated
- 2026-05-22
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Adverse events at 6 months | From enrollment to the end of treatment at 6 months | Within 6 months, the time from randomization to the first occurrence of any of the following events: including gastrointestinal bleeding, new onset or worsening of ascites \> grade II, new onset or worsening of portal vein thrombosis, treatment with interventional transjugular intrahepatic portosystemic shunt (TIPS) or liver transplantation, and occurrence of death. |
| Secondary | Adverse events at 1months | From enrollment to 1months of treatment | Gastrointestinal bleeding, new or aggravated ascites \> Grade II, new or aggravated portal vein thrombosis, treatment with interventional transjugular intrahepatic portosystemic shunt (TIPS) or liver transplantation, death |
| Secondary | Adverse events at 2 months | From enrollment to the 2 months of treatment | Gastrointestinal bleeding, new or aggravated ascites \> Grade II, new or aggravated portal vein thrombosis, treatment with interventional transjugular intrahepatic portosystemic shunt (TIPS) or liver transplantation, death |
| Secondary | liver function at 6 months of treatment | From the enrollment to 6 months of treatment | Changes in liver function at 6 months of treatment measured by ALT/AST/Total Bilirubin level |
| Secondary | renal function at 6 months of treatment | From the enrollment to 6 months of treatment | Changes in renal function at 6 months of treatment measured by serum creatinine level |
| Secondary | Hemodynamic changes at 6 months | From enrollment to the end of treatment at 6 months | flow velocity of the portal vein system (m/s) measured by ultrasound |
| Secondary | Patency of portal vein thrombosis at 6 months | From enrollment to the end of treatment at 6 months | changes of portal vein thrombosis measured by CT Venography at 6 months (progress or recanalization） |
| Secondary | liver stiffness at 6 months | From enrollment to the end of treatment at 6 months | liver stiffness after 6 months of treatment measured by fibroscan |
| Secondary | spleen stiffness at 6 months | From enrollment to the end of treatment at 6 months | spleen stiffness after 6 months of treatment measured by fibroscan. |
| Secondary | Rivaroxaban Plasma Concentration at 6 Months | From enrollment to the end of treatment at 6 months | Changes in Rivaroxaban Plasma Concentration After 6 Months of Treatment |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07602062
GET https://conductscience.org/api/trials/v1/NCT07602062/registered